Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen Completes KAI Acquisition | Contract Pharma

What are you searching for?

Sign in
Breaking News

Amgen Completes KAI Acquisition

Gains thyroid drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen has completion of the acquisition of KAI Pharmaceuticals based in South San Francisco. The acquisition includes KAI’s lead product candidate KAI-4169, a novel drug being studied for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. The drug has successfully completed a Phase II trial in this indication. 
 
Amgen paid $315 million for KAI in an acquisition announced in April 2012.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics